Belmont Diagnostics SAS (France) – Advanced Diagnostics & Biotech Instruments

In an unassuming corner of southern France, a one-person biotech venture is quietly developing technology with outsized strategic implications. Belmont Diagnostics SAS specializes in extracting high-quality blood plasma from a single drop of blood, using a portable device that works “anytime, anywhere”. This novel approach promises to deliver reliable medical test results in minutes, without the need for complex lab infrastructure. Such capability is more than a healthcare innovation; it aligns with Europe’s broader push for technological sovereignty. Recent EU measures even moved to exclude Chinese suppliers from large medical device contracts, underscoring Europe’s desire to cultivate domestic alternatives[1]. Meanwhile, NATO’s 2022 strategic concept elevated biotechnology to a core priority alongside AI and quantum tech[2]. Belmont Diagnostics – though small in size – sits at the nexus of these trends. Its plasma-on-chip solution exemplifies dual-use innovation that could strengthen European autonomy in health security while supporting allied forces with rapid, point-of-care diagnostics. The company’s journey from a local deep-tech startup to a potential enabler of European resilience is an intriguing story of how cutting-edge biotech can serve both civilian medicine and defense readiness.